Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation.

doi:10.1111/epi.16394

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation.

Epilepsia - 1 Dec 2019

Billakota Santoshi, Andresen J Michael, Gay Bryant C, Stewart Gregory R, Fedorov Nikolai B, Gerlach Aaron C, Devinsky Orrin

Abstract excerpt

OBJECTIVE: To screen a library of potential therapeutic compounds for a woman with Lennox-Gastaut syndrome due to a Y302C GABRB3 (c.905A>G) mutation. METHODS: We compared the electrophysiological properties of cells with wild-type or the pathogenic GABRB3 mutation. RESULTS: Among 1320 compounds, multiple candidates enhanced GABRB3 channel conductance in cell models. Vinpocetine, an alkaloid derived from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug
Share to Electroencephalography
Share to gamma-Aminobutyric Acid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HEK293 Cells

Share to Mutation

Share to Neuroprotective Agents

Share to Precision Medicine

Share to Receptors, GABA-A

Source

Open in PubMed Open full text

Identifiers

PMID: 31755996
DOI: 10.1111/epi.16394
PMCID: PMC7004153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.